With no binding to Fc receptors, cadonilimab shows minimal antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and interleukin-6 (IL-6)/IL-8 release, all of which may increase its safety in the treatment of cancer. Here, IL6 is linked to cancer.